Biotechnology company ImaginAb has entered into a new non-exclusive licence and supply agreement with Leucid Bio for CD8 ImmunoPET technology.

ImaginAb will be responsible for licensing and supplying the clinical doses of 89Zr crefmirlimab berdoxam, its investigational CD8 ImmunoPET tracer, to Leucid Bio.

Leucid Bio will use the CD8 ImmunoPET tracer along with LEU011 targeting NKG2DL, autologous CAR T-cells, in its basket study to treat solid tumours.

ImaginAb CEO Ian Wilson stated: “We are delighted that Leucid Bio will use our investigational CD8 ImmunoPET for the first time in conjunction with CAR-T therapies.

“This agreement with Leucid Bio is an opportunity for ImaginAb to continue expanding our partnerships, and showcases the increasing adoption of our CD8 ImmunoPET technology.”

CD8 ImmunoPET (89Zr crefmirlimab berdoxam) is an 89Zr-labeled mini body, designed to bind to CD8 receptors on human T cells for non-invasive, quantitative PET imaging.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The technique is currently being investigated for diagnosing the immune status of a patient, measuring the efficacy of immunotherapies and predicting patients’ outcomes.

Leucid Bio chief business officer Artin Moussavi said: “This is an exciting partnership for Leucid as this cutting-edge technology will provide evidence of the biodistribution of LEU011 CAR T-cells.

“This will be the first time this technology will be used in a solid tumour CAR-T clinical setting, allowing Leucid to generate data that demonstrate the tracking of LEU011 to tumour sites in the first phase of the trial.

“This data would validate in humans the significant improvements already demonstrated with LEU011 in preclinical studies.”

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.